NCT05874193View on ClinicalTrials.gov

A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2027

Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
DRUG

Belantamab mafodotin

Belantamab mafodotin 2.5mg/kg in 42-day cycles. Every 6 weeks until PD, unacceptable toxicity or withdrawal of consent, whichever comes first

Trial Locations (5)

27536

Maria Parham Hospital, Henderson

27570

Johnston Hematology and Oncology of Clayton, Clayton

27577

Johnston Cancer Center, Smithfield

28352

Scotland Health Care System, Laurinburg

28358

UNC Health Southeastern, Lumberton

All Listed Sponsors
lead

Cristiana Costa Chase, DO

OTHER